European Journal of Dermatology
MENUA high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma Volume 28, numéro 1, January-February 2018
Auteurs
Background
1 Department of Dermatology, CHRU, Tours, France
2 PRES Centre, Val de Loire University, University Francois Rabelais de Tours, Tours, France
3 Department of Dermatology, CHR Le Mans, France
4 Department of Dermatology, CHR Orléans, France
5 INSERM CIC 1415, CHRU Tours, France
6 Inserm U 930, University Francois Rabelais, Tours, France
* Reprints
- Mots-clés : neutrophil/lymphocyte ratio, BRAF, prognostic factor, corticosteroid, progression-free survival, melanoma
- DOI : 10.1684/ejd.2017.3167
- Page(s) : 38-43
- Année de parution : 2018
Some studies have shown that a high neutrophil/lymphocyte ratio (NLR) ≥4 before initiating ipilimumab treatment is an independent prognostic indicator of poor survival in patients with metastatic melanoma (MM).